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Transforming growth factor-b activated kinase 1 (TAK1) has been shown to play
a crucial role in cell death, differentiation, and inflammation. Here, we live-
imaged robust TAK1 activation in Lewis lung carcinoma 3LL cells implanted into
the s.c. tissue of syngeneic C57BL ⁄ 6 mice and treated with polyinosinic:poly-
cytidylic acid (PolyI:C). First, we developed and characterized a F€orster resonance
energy transfer-based biosensor for TAK1 activity. The TAK1 biosensor, named
Eevee-TAK1, responded to stress-inducing reagents such as anisomycin, tumor
necrosis factor-a, and interleukin1-b. The anisomycin-induced increase in F€orster
resonance energy transfer was abolished by the TAK1 inhibitor (5z)-7-oxozeae-
nol. Activity of TAK1 in 3LL cells was markedly increased by PolyI:C in the pres-
ence of macrophages. 3LL cells expressing Eevee-TAK1 were implanted into mice
and observed through imaging window by two-photon excitation microscopy.
During the growth of tumor, the 3LL cells at the periphery of the tumor showed
higher TAK1 activity than the 3LL cells located at the center of the tumor, sug-
gesting that cells at the periphery of the tumor mass were under stronger stress.
Injection of PolyI:C, which is known to induce regression of the implanted
tumors, induced marked and homogenous TAK1 activation within the tumor tis-
sues. The effect of PolyI:C faded within 4 days. These observations suggest that
Eevee-TAK1 is a versatile tool to monitor cellular stress in cancer tissues.
T ransforming growth factor b-activated kinase 1 was firstidentified as a MAPK kinase downstream of TGF-b,(1) and
has been shown to mediate Smad-independent TGF-b signaling
to stress-responsive MAPK in a TRAF6-dependent manner,
causing apoptosis and EMT.(2,3) Importantly, TAK1 also func-
tions as a hub to transmit inflammatory signals elicited by
IL-1b and TNF-a to the nuclear factor-jB pathway.(4,5) In the
latter scenario, TAK1 prevents cells from apoptosis by multi-
ple mechanisms.(6–8) The anti-apoptotic role of TAK1 has also
been shown genetically: TAK1-deficient mice are embryonic
lethal(9,10) or, in the case of conditional knockout, are suffering
from dysfunction of the immune system or severe skin inflam-
mation.(11,12) Recently, however, it has been revealed that pro-
longed TAK1 activation induces another type of cell death,
necroptosis, adding further complexity to the known functions
of TAK1 in vivo.(13)
Chronic inflammation contributes greatly to the generation
of the tumor microenvironment, which includes a variety of
cell types such as tumor-associated macrophages and myeloid-
derived suppressor cells.(14,15) Pro-inflammatory cytokines such
as TNF-a and IL-1b are the major players in fostering genera-
tion of the tumor microenvironment in chronic inflamma-
tion.(14,16) Accordingly, TAK1 has been shown to promote
tumor growth in various ways. For example, TAK1 is essential
for TNF-a-mediated metastasis of colon or breast cancer
cells.(17,18) It is also required to inhibit apoptosis in KRas-
transformed cells.(19) In this context, it is worth noting that
tumor-associated macrophages and myeloid-derived suppressor
cells have been shown to be converted into tumoricidal effec-
tors by RNA adjuvant therapy, with TNF-a and IL-1b again
acting as the major mediators.(20) Studies are therefore needed
to determine how the inflammatory cytokine signaling pathway
is regulated in an in vivo setting.
Genetically encoded biosensors based on fluorescent proteins
and FRET have been developed in order to visualize the sub-
cellular activities of signaling molecules.(21,22) Recent progress
has enabled us to follow the activities of small GTPases and
protein kinases for several days under a microscope, opening a
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new window into the signal transduction of cancer cells.(23)
For example, it has been shown that glioma cells exhibit
marked heterogeneity in Rac1 activity and their levels of Rac1
activity have been correlated to their invasion capacities.(24)
More recently, a FRET biosensor for ERK was used to investi-
gate how melanoma cells build a niche to acquire drug
tolerance.(25)
Here we report a novel FRET biosensor for TAK1 activity,
called Eevee-TAK1, based on the optimized backbone.(26)
Lewis lung carcinoma cells expressing Eevee-TAK1 were
implanted s.c. into syngeneic mice and observed for 5 days
through an imaging window by two-photon excitation micro-
scopy. We found that TAK1 activity was higher at the invad-
ing front of the tumor tissues. Treatment with PolyI:C, which
drives macrophages to secrete IL-1b and TNF-a, was found to
evoke strong TAK1 activation diffusely in the tumor tissues.
The combination of FRET biosensors and in vivo imaging will
help us to untangle signaling pathways in living tissue.
Materials and Methods
Plasmids. Construction and stable expression of the FRET
biosensor were carried out as described previously.(26) The
3592NES FRET biosensor was based on the optimized Eevee
backbone, which was comprised of the optimized fluorescent
protein pair, YPet and ECFP, a long flexible EV-linker (116
a.a.), an FHA1 phospho-threonine-binding domain from yeast
Rad53, a substrate sequence, and the NES from HIV-1 rev
protein (LQLPPLERLTLD). The substrate sequence con-
sisted of a.a. 276–295 of human cyclin D1 (EEEEEV-
DLACTPTDVRDVDI), in which the +3 residue from the
target phosphorylation site Thr286 (underlined) was changed to
an Asp (italicized) to increase affinity to the FHA1 domain.
Stable cell lines expressing the 3592NES FRET biosensors were
established by transposon-mediated gene transfer as described
previously.(26,31) An expression vector for an active mutant of
TAK1, TAK1-TAB, was kindly provided by Hiroaki Sakurai.(27)
The plasmid was transfected into HeLa cells expressing
3592NES with 293fectin according to the manufacturer’s proto-
col (Thermo Fisher Scientific, Waltham, MA, USA). The
shRNA sequences inserted into pLKO.1-TRC are shown in
Table 1.(28) Negative control vector containing scrambled
shRNA (#1864) was purchased from Addgene (Cambridge, MA,
USA). The 4T1 cells or 3LL cells were transfected with pLKO-
shTAK1 #1–#5 or scramble control (scr) by Lipofectamine 3000
(Thermo Fisher Scientific), incubated for 2 days, and subjected
to immunoblotting analysis or FRET imaging.
Antibodies and reagents. The following primary and sec-
ondary antibodies were used for immunoblotting analysis and
immunocytochemistry: anti-TAK1 rabbit polyclonal antibody,
anti-phospho-SAPK ⁄ JNK (Thr183 ⁄Tyr185) rabbit polyclonal
antibody, and anti-phospho-p38 MAPK (Thr180 ⁄Tyr182)
antibody (Cell Signaling Technology, Danvers, MA, USA);
anti-TNF Receptor I rabbit polyclonal antibody (Abcam, Cam-
bridge, UK); anti-IL-1 mouse mAb (Santa Cruz Biotechnology,
Dallas, TX, USA); anti-a-tubulin (DM1A) mouse mAb (Merck
Millipore, Billerica, MA, USA); IRDye 680 goat anti-mouse
IgG and IRDye 800CW goat anti-rabbit (LI-COR Biosciences,
Lincoln, NE, USA); and Alexa Fluor anti-mouse F4 ⁄80 anti-
body (BioLegend, San Diego, CA, USA). Mouse IL-1b and
human TNF-a were from Wako (Osaka, Japan).
Blasticidin S and puromycin were purchased from Invivo-
Gen (San Diego, CA). (5z)-7-oxozeaenol, JNK inhibitor VIII,
anisomycin, dibutyryl cyclic AMP, and TPA were purchased
from Merck Millipore. Epidermal growth factor, SB203580,
IMD-0354, and PolyI:C were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The GSK-3b inhibitor, CHIR-99021,
was purchased from Focus Biomolecules (Plymouth Meeting,
PA, USA).
Immunoblotting. HeLa, 4T1, and 3LL cells were lysed in
SDS sample buffer (62.5 mM Tris-HCl [pH 6.8], 12% gly-
cerol, 2% SDS, 0.004% bromophenol blue and 5% 2-mercap-
toethanol). After sonication, the samples were separated by
SDS-PAGE and transferred to PVDF membranes (Merck Milli-
pore). After blocking with Odyssey blocking buffer (LI-COR)
for 30 min, the membranes were incubated with primary anti-
bodies diluted in Can Get Signal (Toyobo, Osaka, Japan), fol-
lowed by secondary antibodies diluted in Odyssey blocking
buffer. Proteins were detected by an Odyssey Infrared scanner
(LI-COR) and analyzed by using the Odyssey imaging soft-
ware.
Cell culture. HeLa cells were purchased from the Human
Science Research Resources Bank (Sennan-shi, Japan) and
maintained in DMEM (Wako) containing 10% FBS (Sigma-
Aldrich) and penicillin–streptomycin (Nacalai Tesque, Kyoto,
Japan) at 37°C in a humidified atmosphere containing 5%
CO2.
Lewis lung carcinoma (3LL) cells were maintained in
RPMI-1640 medium containing 10% FBS and penicillin–strep-
tomycin at 37°C. 4T1 tumor cells were purchased from ATCC
(Manassas, VA, USA) and cultured with RPMI-1640 medium
containing 10% FBS and penicillin–streptomycin at 37°C.
Preparation of macrophages. Bone marrow cells were col-
lected from 8 to 12-week-old C57BL ⁄6 mice. Monocyte sub-
sets were enriched by using an EasySep mouse monocyte
enrichment kit (Stemcell Technologies, Vancouver, BC,
Canada). Isolated monocytes were maintained in RPMI-1640
containing 10% FBS, penicillin–streptomycin, and 10% L929
cell-conditioned medium at 37°C in a humidified atmosphere
containing 5% CO2 on a UPCell dish (CellSeed, Tokyo,
Japan). One to two weeks after isolation, monocytes prolifer-
ated and differentiated into macrophages, and were cocultured
with 3LL cells expressing 3592NES.
Epifluorescence microscopy of tissue culture cells. F€orster (or
fluorescence) resonance energy transfer imaging with an
inverted epifluorescence microscope was carried out essentially
as described previously.(29) Cells were plated on 35-mm glass-
base dishes, cultured for 24 h, and starved for 1 h in phenol
red-free M199 (Thermo Fisher Scientific) containing 0.1%
BSA. Cells were observed with an IX81 inverted microscope
(Olympus, Tokyo, Japan) equipped with a UPlanSApo 40
9 ⁄0.95 dry objective lens (Olympus), PlanApo 609 ⁄1.40 oil
objective lens (Olympus), a CoolSNAP K4 charge-coupled
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device camera (Roper Scientific, Tucson, AZ, USA), a
CoolLED precisExcite LED illumination system (Molecular
Devices, Sunnyvale, CA, USA), an IX2-ZDC laser-based auto-
focusing system (Olympus), and an MD-XY30100T-Meta
automatically programmable XY stage (SIGMA KOKI, Tokyo,
Japan). Fluorescent images were acquired with the following
filters purchased from Omega Optical (Brattleboro, VT, USA):
an XF1071 440AF21 excitation filter, an XF2034 455DRLP
dichroic mirror, and an XF3075 480AF30 emission filter for
CFP, and a XF3079 535AF26 emission filter for FRET.
Images were analyzed with Meta-Morph software (Universal
Imaging, West Chester, PA, USA) as described previously.(29)
Briefly, after background subtraction, FRET ⁄CFP ratio images
were generated in the intensity modulated display mode. For
the time course analysis, fluorescent intensities were averaged
over the whole cell area. The FRET ⁄CFP values were aver-
aged for 10 min before stimulation and used to normalize the
changes in FRET ⁄CFP values during observation.
Mouse allograft model. C57BL ⁄6 mice were housed in a
specific pathogen-free facility and received a routine chow diet
and water ad libitum. Six to sixteen-week-old mice were used
for the in vivo imaging. To prepare tumor-bearing mice, 3LL
cells (5 9 106 cells ⁄ 30 lL PBS) were injected s.c. into the
flank of mice. Tumors that reached to 150–1000 mm3 (approx-
imately 4 days after implantation) were observed under a two-
photon excitation microscope. The animal protocols were
reviewed and approved by the Animal Care and Use Commit-
tee of Kyoto University Graduate School of Medicine (No.
15064) (Kyoto, Japan).
In vivo observation through an imaging window. The
in-house-constructed imaging window consisted of a round
coverslip (CO15001 Φ = 15 mm; Matsunami Glass Industry,
Osaka, Japan) adhered to a ring-shaped magnet (Φ12 9
Φ8.0 9 0.5 mm; Magfine Corp., Miyagi, Japan) with Aron
Alpha (Toagosei, Tokyo, Japan). After shaving, the skin over
the left femur region of a C57BL ⁄ 6 mouse was incised for a
span of 10 mm. The imaging window was inserted into the
incision, which was then stitched with 6-0 nylon sutures (Ethi-
con, Cincinnati, OH, USA). After more than 1 week, a circular
region of skin was removed to expose the imaging window.
The 3LL cells expressing Eevee-TAK1 (5 9 106 in PBS) were
then injected beneath the imaging window. After 4–7 days,
mice were anesthetized with 1.5–2% isoflurane (Abbot, Abbott
Park, IL, USA) inhalation and placed in the prone position on
an electric heating pad maintained at 37°C. The ring-shaped
magnet on the imaging window was attached to the metal
plate, which was held level to the objective lens and imaged
by an upright two-photon excitation microscope. In some
experiments, 20 lL of 7 mM TAK1 inhibitor 5z-7-oxozeaenol
in 25% DMSO ⁄75% PBS solution was injected under the
imaging window with a 29-G needle.
Two-photon excitation microscopy of live mice. We used an
FV1200MPE-BX61WI upright microscope (Olympus) equip-
ped with a 259 ⁄1.05NA water-immersion objective lens
Fig. 1. Development and characterization of the
3592NES F€orster resonance energy transfer (FRET)
biosensor. (a) The 3592NES FRET biosensor
comprised of a cyclin D1-derived substrate peptide
and an FHA1 phospho-amino acid binding domain,
sandwiched with fluorescent proteins YPet and
ECFP. Phosphorylation of the substrate domain
increases FRET. NES, nuclear export sequence. (b)
HeLa cells expressing 3592NES were stimulated with
5 lg ⁄ mL anisomycin at 0 min. FRET ⁄ cyan
fluorescent protein (CFP) images are depicted in the
IMD display mode. Scale bar = 50 lm. (c,d) HeLa
cells expressing 3592NES were stimulated with
several stimuli-inducing reagents: 5 lg ⁄ mL
anisomycin, 1 mM cyclic AMP (Mock), 1 lM TPA,
10 ng ⁄ mL epidermal growth factor (EGF), 270 ng
⁄ mL human tumor necrosis factor-a (hTNF-a), and
10 ng ⁄ mL mouse interleukin-1b (mIL-1b). (c)
Representative time courses of FRET ⁄ CFP values. (d)
Averages at 60 min of more than 20 cells under
each condition from three independent experi-
ments. (e) Lewis lung carcinoma 3LL cells expressing
3592NES were stimulated with 270 ng ⁄ mL TNF-a
and 10 ng ⁄ mL IL-1b. (f) Representative time courses
and averages at 60 min.
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(XLPLN 25XW-MP; Olympus) for the imaging through the
imaging window and an FV1000MVE inverted microscope
(Olympus) equipped with a 309 ⁄1.05NA silicon-immersion
objective lens (UPLSAPO 309S; Olympus). Both microscopes
are also equipped with an InSight DeepSee Ultrafast laser
(Spectra Physics, Mountain View, CA, USA), two GaAsP
detector units, and two built-in photomultiplier tubes. The laser
power used for observation was 10–20%. The scan speed was
set at 2 ls ⁄pixel. The excitation wavelength for CFP was
840 nm. We used an IR-cut filter, BA685RIF-3, two dichroic
mirrors, DM505 and DM570, and three emission filters,
BA460-500 (Olympus) for CFP, BA520-560 (Olympus) for
YFP, and 645 ⁄60 (Chroma Technology Corp. Bellows Falls,
VT, USA) for Alexa 647. Acquired images were analyzed with
MetaMorph software (Molecular Devices) as described previ-
ously.(30)
Statistical analysis. P-values for normal distributed data
were calculated with Student’s t-test or paired Student’s
t-test for the evaluation of statistically significant differences.
Otherwise, the Mann–Whitney U-test was used. Data analy-
sis was carried out using Prism software (GraphPad Soft-
ware, San Diego, CA, USA). *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
Results
Response of FRET biosensor 3592NES to stress-inducing
reagents. The Eevee FRET biosensor 3592NES was originally
designed to monitor GSK-3b activity in living cells. The
3592NES biosensor includes a 20-a.a. peptide derived from
cyclin D1 peptide and known to be a phosphorylation site of
GSK-3b (Fig. 1a). However, in our preliminary experiments,
3592NES did not respond to any GSK-3b-dependent stimuli or
specific inhibitors against GSK-3b or cyclin-dependent protein
kinases. During the course of characterization, however, we
found that 3592NES responded markedly to anisomycin, sug-
gesting that 3592NES may respond to stress-related kinases. In
HeLa cells expressing 3592NES, anisomycin strongly
increased the FRET ⁄CFP ratio (Fig. 1b,c). Furthermore, stress-
inducing cytokines, human TNF-a and mouse IL-1b, were also
found to increase the FRET ⁄CFP ratio in HeLa cells (Fig. 1c,
d) and 3LL cells (Fig. 1e,f). In contrast, growth-promoting
reagents such as epidermal growth factor or TPA did not
increase the FRET ⁄CFP ratio. Interestingly, the 3592NES-
expressing HeLa cells responded more strongly to human
TNF-a than mouse IL-1b, whereas 3LL cells responded more
strongly to mouse IL-1b than human TNF-a (Fig. 1c–e). The
expression of receptors for TNF-a and IL-1b in HeLa cells
and 3LL cells was within a comparable range (Fig. S1A). Of
note, HeLa cells were found to respond more strongly to
human IL-1b than mouse IL-1b (Fig. S1B). This observation
was confirmed by the immunoblotting for active p38 MAPK
and JNK (Fig. S1C–E).
Requirement of TAK1 for stimulation-induced increase in FRET
⁄CFP of 3592NES. To identify the kinase that phosphorylated
3592NES in response to stress-inducing stimuli, we searched
for inhibitors that would abrogate the anisomycin-induced
increase in FRET ⁄CFP in 3592NES-expressing cells. Treat-
ment with the TAK1 inhibitor, but not with other inhibitors for
p38, JNK, IKK, or GSK-3b, completely suppressed the
increase in FRET ⁄CFP ratio (Fig. 2a). This result strongly sug-
gested that 3592NES monitors TAK1 activity (Fig. 2b), or pro-
tein kinases downstream of TAK1. To confirm that 3592NES
monitors TAK1 activity, we next examined the effect of an
active TAK1. As TAK1 is known to be activated by binding
to TAB 1, we used a TAK1–TAB 1 fusion protein as the
Fig. 2. Characterization of 3592NES as a trans-
forming growth factor-b activated kinase 1 (TAK1)
biosensor. (a) HeLa cells expressing 3592NES were
time-lapse imaged without or with 3 nM (5z)-7-
oxozeaenol TAK1 inhibitor, 10 lM SB203580 p38
inhibitor, 10 lM JNK inhibitor VIII, 50 lM IMD-0354
inhibitor of nuclear factor-jB (NF-jB) kinase (IKK)
inhibitor, or 10 lM CHIR99021 glycogen synthase
kinase-3b (GSK-3b) inhibitor. The increase in F€orster
resonance energy transfer ⁄ cyan fluorescent protein
(FRET ⁄ CFP) was scored at 60 min after the addition
of 5 lg ⁄ mL anisomycin for more than 10 cells
under each condition (bars indicate SD; **P < 0.01).
(b) Flow chart of the signaling pathway of TAK1. IL-
1b, interleukin 1b; TNF-a, tumor necrosis factor-a.
(c) HeLa cells expressing 3592NES were mock-
transfected or transfected transiently with an
active-TAK1 expression vector, and examined to
determine their FRET ⁄ CFP values with a fluorescent
microscope. A histogram for the FRET ⁄ CFP values is
shown (mock, n = 188; active-TAK1, n = 81). (d) 4T1
cells were infected with lentiviruses carrying shRNA
against TAK1. Cell lysates were analyzed by
immunoblotting with anti-TAK1 antibody. (e)
3592NES-expressing 3LL cells were infected with
lentivirus carrying shRNA for TAK1 and stimulated
with 10 ng ⁄ mL IL-1b (10 ng ⁄ mL). The increase in
FRET ⁄ CFP 60 min after stimulation was scored
(n ≥ 15; ****P < 0.0001). Scr, Scramble control.
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active-TAK1.(31) HeLa cells transfected transiently with the
expression vector for active-TAK1 showed a marked increase
in the fraction of cells showing a high FRET ⁄CFP ratio in
comparison with the mock-transfected cells (Fig. 2c). Next, to
knockdown TAK1, we prepared five shRNAs for TAK1 and
used the two shRNAs (#2 and #4) that exhibited the highest
knockdown efficiency in the following experiments (Fig. 2d).
Depletion of TAK1, induced by the two shRNAs, suppressed
the IL-1b-stimulated increment of the FRET ⁄CFP ratio in 3LL
cells (Fig. 2e). Based on these results demonstrating that
3592NES reflects cellular TAK1 activity, we renamed
3592NES as Eevee-TAK1 and used it in the following study.
Activation of TAK1 in 3LL cells by PolyI:C-stimulated macro-
phages. With the Eevee-TAK1 biosensor in hand, we
attempted to monitor the TAK1 activity of cancer cells, which
are under the stress of immunological surveillance by the host.
We used cells of the Lewis lung carcinoma cell line 3LL,
which are known to be rejected by macrophages stimulated
with double-stranded RNA analog PolyI:C.(20) The 3LL cells
stably-expressing Eevee-TAK1 were imaged in the presence or
absence of macrophages derived from syngeneic C57B6 ⁄L
mice. The activities of TAK1 in 3LL cells showed modest
heterogeneity and changed during observation (Fig. 3a). By
the addition of PolyI:C to the co-culture of 3LL cells and
macrophages, TAK1 activity in most 3LL cells increased
within 740 min (Fig. 3b). For the precise evaluation of the
effect of macrophages and PolyI:C, we randomly chose more
than 60 cells and measured the FRET ⁄CFP ratio in each condi-
tion (Fig. 3b–f). Addition of PolyI:C alone slightly increased
TAK1 activity in 3LL cells (Fig. 3d). Co-culture with macro-
phages also increased TAK1 activity in 3LL cells within
740 min (Fig. 3e). The strongest TAK1 activation was
observed when both PolyI:C was added in the presence of
macrophages (Fig. 3f). This observation is consistent with the
previous report showing that PolyI:C stimulates secretion of
tumoricidal cytokines from macrophages.(20)
In vivo imaging of TAK1 activity in implanted 3LL cells. To
examine the role of TAK1 in tumor growth, 3LL carcinoma
cells expressing Eevee-TAK1 were implanted into the s.c. tis-
sue of syngeneic C57BL ⁄6 mice and observed repeatedly
through an imaging window (Fig. 4a,b). First, an imaging win-
dow consisting of a cover glass and a magnet ring was surgi-
cally implanted under the skin of a mouse hind leg. After
several days, when the inflammation caused by the surgery
had subsided, 3LL cells were inoculated under the imaging
window. Tumors grew to approximately 2 mm in diameter
within 4 days. Before image acquisition, the magnet ring of
the imaging window was used to level the cover glass to the
fixing implement, which minimizes motion artifacts caused by
heartbeats and breathing. Then the cancer tissues were
observed by an upright two-photon excitation microscope to
acquire FRET images. We could clearly distinguish each
tumor cell and found that 3LL cells close to the surrounding
host tissues exhibited high TAK1 activity (Fig. 4c). During
5 days observation, the high TAK1 activity was confined to
the cells locating at the periphery of the tumor mass. To
exclude the possibility that the gradient of the FRET ⁄CFP ratio
in the tumor tissue was an artifact, we used 3LL cells express-
ing a negative control FRET biosensor AKAREV-NC, in
which the phosphorylation site of the FRET biosensor was
Fig. 3. Activation of transforming growth factor-b
activated kinase 1 (TAK1) by polyinosinic:
polycytidylic acid (polyI:C)-stimulated macrophages.
3LL cells expressing 3592NES were cultured alone
(a, c). 3LL cells expressing 3592NES with 50 lg ⁄ mL
PolyI:C (d), or cocultured with macrophages (MΦ) in
the absence (e) or presence (b, f) of PolyI:C. Cells
were imaged under an epifluorescence microscope
(scale bar = 50 lm) and quantified for Fo¨rster
resonance energy transfer ⁄ cyan fluorescent protein
(n ≥ 60; **P < 0.01).
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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substituted with alanine.(30) As shown in Figure 4(d), the 3LL
cells expressing AKAREV-NC did not show a remarkable
gradient in the FRET ⁄CFP ratio. To confirm that the high
FRET ⁄CFP ratio in the tumor tissue reflected TAK1 activity,
TAK1 inhibitor (5z)-7-oxozeaenol was injected below the
imaging window (Fig. 4e). As expected, the TAK1 inhibitor
robustly decreased the FRET ⁄CFP ratio.
Polyinosinic:polycytidylic acid-induced TAK1 activation
in vivo. Activation of innate immunity mediated by PolyI:C is
known to induce the regression of 3LL cells in a syngeneic
transplantation model. Therefore, we next examined the effect
of PolyI:C on TAK1 activity. Twenty-four hours after injec-
tion, TAK1 activity was robustly elevated in almost all cells
within the tumor tissue including the 3LL cells located at the
periphery (Fig. 5a,b). Interestingly, a quantity of 3LL cells at
the border of tumor tissues showed marked changes in shape:
the round 3LL cells became spindle-shaped, extended cellular
processes, and appeared to have begun invading into the sur-
rounding tissues; these are all typical morphological changes
of EMT, therefore EMT might have occurred (Fig. 5c). The
high TAK1 activity subsided within 4 days to restore the origi-
nal morphology and gradient of TAK1 activity. Notably, the
second PolyI:C injection induced TAK1 activation again, indi-
cating that the decrease of TAK1 activity on day 4 was caused
by the decrease of PolyI:C in the tissue, rather than by the
adaptation of tumor cells to PolyI:C (Fig. 5a).
Polyinosinic:polycytidylic acid is thought to cause tumor
necrosis through cytokines secreted from myeloid-derived cells
among the tumor cells. We speculated that the enrichment of
the myeloid-derived cells at the periphery of the tumor mass
may have caused the TAK1 activity gradient in the tumor tis-
sue. To visualize the localization of the myeloid-derived cells
in and around the allograft, we injected Alexa Fluor 647 anti-
mouse F4 ⁄80 antibody, a marker for mature macrophages and
monocytes, into the tumors in the absence of PolyI:C. The F4
⁄80-positive cells were distributed in and around the tumor,
negating the possibility that the gradient of TAK1 activity in
the tumor reflected the localized recruitment of myeloid cells
(Fig. 5d).
Discussion
In this study, we developed Eevee-TAK1, a new FRET-based
biosensor monitoring TAK1 activity in living cells, and
detected TAK1 activity at single-cell resolution. With Eevee-
TAK1, we found that TAK1 activity was significantly higher
in 3LL cells locating at the periphery of the tumor than in
3LL cells locating at the center of the tumor (Fig. 4c).
Because TAK1 responds to inflammatory stresses,(6–8) we
speculated that inflammatory cytokines or direct interaction
with antitumor immune cells caused TAK1 activation in the
tumor cells locating at the periphery of the tumor. However,
against our expectation, F4 ⁄80-positive macrophages were
observed diffusely in the tumor tissues (Fig. 5c). It is still pos-
sible that macrophages surrounding the tumor cells are more
active than the macrophages within the tumor cells, which
should be examined in a future study.
The high level of TAK1 activity in the peripheral tumor
cells is reasonable if we consider the positive role of TAK1 in
EMT.(2,3) In agreement with this reasoning, we found that
PolyI:C treatment causes significant TAK1 activation and
EMT-like morphological changes of 3LL tumor cells at the
periphery of the tumor cells (Fig. 5b). However, in our prelim-
inary experiments, we failed to detect the induction of EMT
markers such as E-cadherin, a-smooth muscle actin, Snail, or
vimentin. Therefore, it is currently unknown whether the high
Fig. 4. Intravital imaging of transforming growth
factor-b activated kinase 1 (TAK1) activity in an
allograft model of Lewis lung carcinoma. (a)
Schematic view of the imaging window consisting
of a cover glass and a magnet ring. Several days
after the operation, 3LL cells were inoculated under
the imaging window. (b) The magnet ring of the
imaging window was used to level the cover glass
to the fixing implement, which minimizes motion
artifacts caused by heartbeats and breathing. (c)
3LL cells expressing the TAK1 biosensor 3592NES
were observed by an upright two-photon excitation
microscope to acquire F€orster resonance energy
transfer (FRET) images. From 4 days after
inoculation, the same tumor was observed at days
1, 2, 4, and 5. (d) 3LL cells expressing 3592NES and
a negative control FRET biosensor AKAREV-NC
(PKA-NC) were observed under the same imaging
conditions. Similar results were obtained in three
independent experiments. (e) 3LL cells expressing
3592NES were inoculated as described and imaged
before and 1 h after injection of TAK1 inhibitor
(5z)-7-oxozeaenol.
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TAK1 activity at the peripheral region of the tumor is related
to EMT.
Phosphorylation of Thr286 of cyclin D1 plays a critical role
in its cell cycle-dependent degradation.(32,33) Originally, GSK-
3b was believed to be responsible for Thr286 phosphorylation,
but a later study showed that the checkpoint kinases ATR
and ATM primarily phosphorylate Thr286 during the cell
cycle.(34) More recently, DYRKs have also been shown to
phosphorylate cyclin D1 on Thr286 and regulate the cell
cycle.(35,36) We failed to detect cell cycle-dependent changes
in the FRET signal in HeLa cells expressing the TAK1
biosensor (data not shown). Moreover, none of the inhibitors
against GSK-3b, ATM ⁄ATR, and DYRKs suppressed the ani-
somycin- or TNF-a-induced increase in the FRET signal of
the 3592NES TAK1 biosensor. Nevertheless, we should keep
in mind that these observations do not negate the possibility
that GSK-3b, ATM ⁄ATR, and DYRKs may contribute the
FRET signal in the TAK1 biosensor-expressing cells under
different conditions.
One of the most difficult tasks in the development of a
FRET biosensor for a protein kinase is the selection of a sub-
strate peptide that is specific to the protein kinase of interest.
With the ongoing progress in phospho-proteomics, more than
100 000 human protein phosphorylation sites are now depos-
ited in PhosphoSitePlus and other databases.(37) Recently, sub-
strate databases of protein kinases have also been constructed
by a novel method named KISS.(38) These bidirectional
approaches will help identify the consensus phosphorylation
sequence of each protein kinase, which in turn will assist in
the development of FRET biosensors for protein kinases.
Although a consensus phosphorylation sequence of TAK1 was
reported previously, most of the known substrates did not
match this consensus sequence (Table S1). Therefore, it
remains unknown why the amino acid sequence encompassing
Thr286 of cyclin D1 served as an effective sensor for TAK1
activity. Moreover, in our experience, most of the reported
consensus sequences for the protein kinases were not suffi-
ciently specific for the individual kinases. For example, in the
case of the FRET biosensor for ERK and JNK, in addition to
the consensus phosphorylation sequences, docking sequences
are required for the endowment of specificity to the biosen-
sors.(39,40) Therefore, the cyclin D1 sequence used in Eevee-
TAK1 may coincidentally include the docking sequence to
TAK1.
In conclusion, by using our newly developed TAK1 biosen-
sor and an imaging window for in vivo imaging, the states of
stress in tumor cells could be visualized for several days or
more. This technique should open a new window onto the spa-
tiotemporal effects of antitumor drugs during the induction of
tumor necrosis.
Fig. 5. Polyinosinic:polycytidylic acid (PolyI:C)-induced transforming growth factor-b activated kinase 1 (TAK1) activation in vivo. 3LL Lewis lung
carcinoma cells expressing 3592NES were implanted below the imaging window. (a) F€orster resonance energy transfer (FRET) images from days 0
to 8. Subcutaneous injection of 200 lg PolyI:C was carried out on day 0, just after image acquisition, and day 7. (b) FRET ⁄ cyan fluorescent pro-
tein ratio was plotted along the white lines in (a). Asterisks indicate the origin. (c) Regions marked by white boxes in (a) are enlarged to show
PolyI:C-induced morphological changes. (d) Macrophages beneath the window were marked with Alexa Fluor 647 anti-mouse F4 ⁄ 80 antibody.
Right panel, merged image of white-boxed regions.
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ATR ATM and RAD3-related
CFP cyan fluorescent protein
DYRK dual-specificity tyrosine phosphorylation-regulated kinase
EMT epithelial mesenchymal transition
IL-1b interleukin 1-b
GSK-3b glycogen synthase kinase-3b
NES nuclear export signal
PolyI:C polyinosinic:polycytidylic acid
TAB1 TAK1-binding protein 1
TAK1 TGF-b activated kinase 1
TGF-b transforming growth factor-b
TNF-a tumor necrosis factor-a
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